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Abstract 
Purpose: The aim of this study was to analyze 
the recurrence rate of pterygium following excision 
with intra-operative mitomycin C (MMC) and post-
operative scraping of the perilimbal conjunctival 
defect, and the patients’ satisfaction with this 
technique. 
Methods: This is a retrospective analysis of a 
cohort of 33 eyes of 28 patients with primary or 
recurrent pterygium who underwent simple excision 
with MMC.  They were followed up after a mean of 
27.8 months. The main outcomes considered were 
the recurrence rate and patient satisfaction.  A 
recurrence was defined as any regrowth of 
conjunctiva over the limbus and any complications 
were considered significant. The patients were 
interviewed with a standard questionnaire and 
examined.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: An objective recurrence was noted in 
55% (18 out of 33 eyes).  The recurrence rate after 
excision of primary pterygia was 46% (13 out of 28 
eyes), and for recurrent pterygia it was 80% (four 
out of five eyes).  In this study the complications 
included: six eyes that developed a granuloma, one 
case of bleeding which persisted for three days 
post-op, and one eye in which there was a suspected 
scleral melt at five weeks.  79% of the procedures 
resulted in a good patient satisfaction (26 out of 33 
eyes), and only in 15% (five eyes) was there a 
subjective recurrence.  
Conclusions: This technique in our study 
resulted in an unacceptably high recurrence rate, 
especially in the case of recurrent pterygia.  
However, patients still tended to be satisfied with 
the outcome.   
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Introduction 
A pterygium is a superficial, usually 
elevated, wing-shaped fold of conjunctiva that 
grows over the limbus and extends onto the corneal 
surface. Pterygia can vary from small, atrophic, 
quiescent lesions to large, aggressive, rapidly-
growing fibrovascular lesions that can distort the 
corneal topography, and in advanced cases, obscure 
the optical centre of the cornea.   
Pterygia are described as a proliferative 
disorder resembling an aberrant wound healing 
response.1 It is a disease of limbal stem cells which 
are damaged primarily by chronic UV light 
exposure causing up-regulation of the p53 tumour 
suppressor gene.  This leads to decreased apoptosis, 
increased activity of matrix metalloproteinases 
resulting in Bowman’s layer dissolution, activation 
of cytokines and growth factors resulting in 
leukocytic infiltration, and activation of fibroblasts 
causing increased elastin deposition. The limbal 
predilection may be explained by the phenomenon 
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of peripheral light focusing, in which incident light 
passes through the anterior chamber and is focused 
at the distal (nasal) limbus where limbal stem cells 
reside. 
Typically, a pterygium consists of three 
distinct parts: cap, head, and body/tail. The cap or 
leading edge is a flat zone on the cornea that 
consists mainly of fibroblasts that invade and 
destroy Bowman’s layer. The head is a vascular 
area that lies behind the cap and is firmly attached 
to the cornea.  The body/tail is the mobile area of 
the bulbar conjunctiva, which can be easily 
dissected from the underlying tissue.  Lesions larger 
than 3.5mm on the cornea are likely to be 
associated with more than one dioptre of 
astigmatism.  
The main indications for surgical removal are: 
discomfort despite lubricants, decreased vision, 
diplopia, and cosmetic intolerance.  Several surgical 
techniques exist and the best method would ideally 
have the least rate of recurrence and a short 
operating time. Techniques used are: 
- Bare sclera technique – this has the highest
rate of recurrence but relatively short
operating time.2
- Conjunctival autograft technique – using
sutures, fibrin glue, or autologous blood to fix
the graft onto the scleral bed3; associated with
less recurrence rate but longer operating time.
- Amniotic membrane graft (AMG) – fixed
using sutures or fibrin glue; it is a useful
alternative to conjunctival autografting
especially in patients who have limited
amount of conjunctiva. However, there is the
issue of availability of such materials and
most studies report a significantly higher rate
of recurrence with AMG.4
Adjunctive therapies include the use of
intraoperative mitomycin C (MMC) due to its anti-
fibrotic and anti-angiogenic properties, or β-
radiation; the latter is no longer in use due to its 
adverse effects on the eye.  
MMC alkylates and cross-links DNA, and 
inhibits DNA, RNA, and protein synthesis.  It 
probably has a long-term influence on cellular 
proliferation.5 It is thus used as a fibroblast 
inhibitor.  The use of topical MMC as an adjunct to 
pterygium surgery was first introduced by 
Kunitomo and Mori in Japan and subsequently by 
Singh et al.6 Recurrence rates are reported to be 
5.4–21% when MMC is used alone in treating 
primary pterygium and 12.5–19.2% when treating 
recurrent pterygium.7 Various studies have shown 
that using MMC in patients with more severe 
pterygia as an adjunct to conjunctival autografting, 
lowers the recurrence rate. 
In this study we are investigating the outcome 
with the bare sclera technique augmented with 
intra-operative MMC, followed by post-operative 
scraping of the scleral bed until corneal re-
epithelialization. 
Methods 
This is a retrospective analysis of a cohort of 
33 eyes of 28 patients who underwent primary or 
recurrent pterygium excision with intra-operative 
MMC in the same institution between November 
2011 and December 2013. The procedures were 
carried out by six different surgeons – one 
consultant and five different trainees of varying 
experience (Table 1).   
Table 1: Breakdown of the surgeons involved 
according to surgical experience 
Level of experience Number of procedures 
Consultant 4 
Young trainee 1 1 
Young trainee 2 1 
Senior trainee 1 9 
Senior trainee 2 9 
Senior trainee 3 9 
The patient list was obtained from the 
database supplied by the surgical performance unit 
of the hospital.  Formal ethics and data access 
approvals were granted.  The patients were selected 
sequentially from the list in chronological order.  
The inclusion criterion was pterygium excision with 
intra-operative MMC and post-operative scraping as 
explained in this section.  Exclusion criteria were: 
incomplete information including poor 
documentation, patients lost to follow-up and those 
who could not be contacted or come for the 
examination, and patients in whom the method of 
excision was different from the one described 
below.   
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Table 2: Data entry form devised for this study 
ID 
Name & Surname 
Age now 
Procedure details 
Side 
Date of procedure 
Surgeon performing procedure 
Months since procedure 
Duration of pterygium prior to excision 
Is indication for surgery clearly documented? 
Pre-op VA 
Pre-op size documented 
Pre-op size /mm 
Primary / recurrent pterygium 
Biopsy submitted  Y/N 
Indication for surgery:   Objective 
 Subjective 
Pain / foreign body sensation during surgery 0-10 
Pain / discomfort post-op (during recovery) 0-10 
Pain / foreign body sensation during post-op scrapings 0 - 10 
No. of scrapings 
Timing of scraping (days post-op) 
Duration of post-op antibiotic & steriod regimen 
Antibiotic & steriod regimen 
Post-op lubricants Y/N 
Peri-op complications 
Post-op complications 
Is the patient happy with the result? 
Would the patient do this procedure again for a pterygium in 
the other eye? 
Would the patient do this procedure again for a pterygium in 
the same eye? 
Sunglasses being used regularly in the sun Y/N 
Lubricants being used Y/N 
Subjective recurrence Y/N 
VA post-op (from file) and/or today 
Objective recurrence Y/N 
Size of recurrent pterygium, if present 
Examination findings 
Other remarks 
The notes of the patients included in the study 
were reviewed, and the patients were called for 
questioning throughout the year 2015. A 
questionnaire devised by the study group was used 
(Table 2), and the patients were examined to assess 
for recurrent growth. As shown in Table 2, patients 
were also asked about use of lubricating drops and 
UV protection with sunglasses. A recurrence was 
defined as any growth of conjunctiva beyond the 
limbus. Patients were asked to recall the discomfort 
felt on scraping of the scleral bed carried out during 
the early post-operative reviews under topical 
anaesthesia with 0.4% oxybuprocaine.   
The procedures were all done under local 
anaesthesia using topical 0.4% oxybuprocaine and 
subconjunctival 2% lignocaine with 1:200,000 
adrenaline.  The pterygium was excised from the 
cornea under an operating microscope, with 
attention to remove as much fibrovascular tags as 
possible. The excision included the adjacent 
thickened bulbar conjunctiva and underlying 
Tenon's capsule.  This was followed by the 
application of 0.04% mitomycin C for two minutes 
on the scleral bed using soaked spear swabs 
avoiding contact with the limbus and cornea, 
followed by immediate copious irrigation of the 
conjunctival sac.   
The typical post-operative regimen was a 1% 
chloramphenicol ointment patch till the following 
day.  The patients were closely monitored early on 
and scraped as needed in an attempt to achieve 
healing of the cornea before the perilimbal 
conjunctival defect. The patients were mostly 
reviewed the first time on day 1-2 and the slough 
developing on the scleral bed was scraped away 
from the limbus with a cotton tip or the side of a 
wide-bore needle/blade. Further scraping was 
repeated until the corneal epithelium healed 
completely.  The typical treatment prescribed was a 
combination of 0.3% tobramycin and 0.1% 
dexamethasone as ointment bd and as drops qds for 
3-4 weeks.
Results 
The male-to-female ratio was 3:1 and the 
mean age was 59.4 years (range: 31-86 years).  
There were four temporal pterygia, and five 
recurrent nasal pterygia.  The patients were 
followed up after a mean of 27.8 months (SD: 8.9 
months; maximum follow-up: 44 months).   
The mean time that the patient spent in theatre 
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was 25 minutes (SD: 8.6 minutes; range: 15-45 
minutes). 
In this study the complications included: six 
eyes that developed a granuloma, one case of 
bleeding which persisted for three days post-op, and 
one eye in which there was a suspected scleral melt 
at five weeks.  The granulomas were treated first-
line with intensive application of topical steroids, 
and the case of possible melting was managed with 
a conjunctival advancement.  
An objective recurrence was noted in 55% (18 
out of 33 eyes).  This included minimal overgrowth 
on the cornea.  The recurrence rate after excision of 
primary pterygia was 46% (13 out of 28 eyes) and 
for recurrent pterygia it was 80% (four out of five 
eyes).  The earliest recurrence was documented at 
four months.   
Data on patient satisfaction showed that 79% 
were happy with the result (26 out of 33 eyes), and 
only 15% had noted a recurrence (five eyes).  88% 
said that they would be happy to do same procedure 
again on the same eye if a recurrent pterygium were 
to be removed.  During the post-operative scrapings 
the mode pain score was 0/10, with a mean of 1/10. 
Figure 1 shows the breakdown of subjective 
and objective indications for excision in our group 
of patients. 
In the group of patients studied, only one 
excision specimen was submitted for histology.  
This was a case of a bilobed pterygium and it was 
submitted to exclude possible carcinoma due to the 
temporal component.   Features characteristic of a 
pterygium were confirmed by the pathologist.   
Only 24% said that they used lubricating 
drops post-op (eight out of 33 eyes).  
Discussion 
Over the past couple of decades, there has 
been a significant advancement in pterygium 
surgery techniques that has led to an increased 
variety of options available for the ophthalmic 
surgeon. In this study, MMC was used intra-
operatively and patients were monitored closely 
post-operatively with conjunctival scraping if 
needed, in an attempt to achieve healing of the 
corneal epithelium before that of the perilimbal 
conjunctiva.  
Data collected in this study reports an 
objective recurrence in 55% (18 out of 33 eyes). 
While the recurrence rate after excision of primary 
pterygia was 46% (13 out of 28 eyes), that for 
recurrent pterygia was reported to be 80%. The fact 
that 79% of patients were satisfied with the result 
indicates that the patients were asymptomatic. 
The use of high cumulative doses of MMC 
post-operatively, as well as poor selection of 
patients, can lead to the development of severe 
complications. To limit these complications, it is of 
utmost importance to set strict exclusion criteria, to 
use MMC only intra-operatively under controlled 
conditions, and to follow the patients closely until 
ocular surface re-epithelialization is complete.8   
Patients suffering from conditions that 
predispose to poor wound healing should not be 
treated with MMC. These include patients with 
atopic keratoconjunctivitis, severe dry eye, acne 
rosacea, and herpes keratitis. Possible complications 
that can arise from the uncontrolled use of MMC or 
its use in high-risk patients include: corneal oedema 
or perforation, corectopia, iritis, scleral 
calcification, pain, secondary glaucoma, and 
cataract.9  
Varying concentrations of MMC have been 
used intra-operatively, usually in the range of 0.02-
0.04%. Also, the time of exposure of MMC to the 
subconjunctival space varies in different studies, 
usually from one to five minutes. In this study, the 
concentration of MMC used was 0.04% and the 
intra-operative exposure time was two minutes. 
This large variation makes it difficult to compare 
the results.  The safest concentration and exposure 
time of intra-operative MMC that are effective in 
preventing pterygium recurrence without causing 
complications have still not been established. More 
large-scale prospective studies will need to be 
carried out to reach a conclusion.   
Table 3 summarizes the findings of a meta-
analysis carried out by Sanchez-Thorin et al,10 and 
studies by Manning and Young.11-12 In the latter 
two studies, the sclera was covered by conjunctiva 
at the end of the procedure.  
Pterygium excision with conjunctival 
autograft is time-consuming and has a significant 
learning curve. Surgeons may also be reluctant to 
use a conjunctival autograft in patients who may 
need the conjunctiva for future surgical procedures. 
On the other hand, avoiding the use of MMC will 
not expose the patients to its possible side-effects, 
even though these are uncommon when MMC is 
used appropriately.    
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Appearance
35%
Irritation
24%
Visual
12%
Nil
29%
Size
46%
Vision
9%
Inflammation
9%
Symptoms
11%
n/a
26%
Figure 1: Indications for pterygium excision: Chart 1a - Subjective; Chart 1b – Objective 
Chart 1 a – Subjective 
Chart 1 b – Objective 
In our study, the rate of recurrence in primary 
pterygia was 46%. However, this percentage also 
included minimal overgrowth on the cornea 
(<1mm), therefore comparison to these studies is 
difficult since the definition of recurrence varied.  
For example, some defined recurrence as a 
regrowth of >1.5mm.11 However, a recurrence 
actually starts when there is a reactivation of the 
inflammatory process (vascular congestion and 
thickening) in the treated area.13 It should be noted 
that our first recurrence was documented at four 
months, even though usually recurrences occur in 
the first three months after excision.14 Our method 
could thus have retarded the recurrence. Further 
studies would be needed to establish whether this 
effect is statistically significant.   
Also, one has to take into consideration the 
high UV index the Maltese population is exposed to 
throughout the year (Mediterranean climate), the 
ever-increasing environmental pollutants, and 
possible genetic factors that may influence 
recurrence rates.   
As mentioned previously, pterygium excision 
with conjunctival autograft is time-consuming and 
has a steep learning curve. Variations to this 
procedure include the use of intra-operative MMC 
combined with closure of the conjunctiva to the 
limbus, thus avoiding bare sclera. This was reported 
to give good results and at the same time decrease 
the possible complications caused by MMC.15 In 
addition, this approach does not increase the 
procedure time significantly, therefore providing a 
good compromise.    
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Table 3: Summary of findings of a meta-analysis by Sanchez-Thorin et al 1998 (12) 
Author Year of 
publication 
Technique Number 
of Eyes 
MMC 
concentration 
(%) 
MMC 
contact 
time 
(minutes) 
Recurrence 
rate (%) 
Lewallen 1989 Bare sclera 16 n/a n/a 40.0 
Chen et al 1995 Bare sclera 17 n/a n/a 88.2 
Singh et al 1988 Bare sclera 18 n/a n/a 88.9 
Mahar, Nwokora 1993 Bare sclera 15 n/a n/a 60.0 
Manning et al 1997 Intra-
operative 
MMC 
19 0.04 3 10.5 
Young et al 2004 Intra-
operative 
MMC 
53 0.02 5 15.9 
Chen et al 1995 Conjunctival 
autograft 
23 n/a n/a 39.1 
Lewallen 1989 Conjunctival 
autograft 
17 n/a n/a 17.6 
Manning et al 1997 Conjunctival 
autograft 
18 n/a n/a 22.2 
Young et al 2004 Conjunctival 
autograft 
52 n/a n/a 1.9 
Manning et al 1997 Post-
operative 
MMC 
19 0.02 qds x1 wk 21.1 
Chen et al 1995 Post-
operative 
MMC 
24 0.02 bd x5 days 37.5 
Mahar, Nwokora 1993 Post-
operative 
MMC 
17 0.04 qds x2 
wks 
0 
The main strength of this study is the long 
follow-up period. However, there were several 
limitations in this study. The sample size was small, 
and having different surgeons produces operator 
bias. With multiple surgeons there is variation in 
technique, and procedures carried out by trainee 
surgeons at different stages in their training were 
included. It is difficult to standardize quality of 
excision, even by the same surgeon. In addition, 
since this was a retrospective study, there is a 
likelihood of recall bias by the patients when they 
were questioned regarding their experience; a 
prospective approach would have been better to 
decrease recall and selection bias, and improve the 
quality of the data. A visual analogue pain scale 
could have been better suited for patients to grade 
pain. Also, it is difficult to ensure patient 
compliance with the post-operative treatment and 
precautions. This is important since limited use of 
post-operative topical steroid is associated with a 
higher risk of recurrence.16 There are other 
confounding factors which influence the risk of 
recurrence, such as sun exposure and dry eye 
disease, but these are very difficult to control.   
In our study the recurrence rate after recurrent 
pterygium excision was very high and this indicates 
that MMC alone is not sufficient for recurrent 
pterygia; even the overall recurrence rate was 
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unacceptably high.  However, for patients who are 
unlikely to tolerate a long operation time for various 
reasons, this method remains an option, provided 
that the patient is aware of the higher recurrence 
rate.   
 Possible improvements on the intra-operative 
MMC method may be: increasing the MMC 
exposure time, and meticulous clearance of the 
limbus to remove all the vascular bridges. 
 The use of lubricants and sunglasses should be 
encouraged, especially in early pterygia and 
following excision, as this can decrease symptoms 
and possibly slow progression or recurrence.  
 
Acknowledgements 
Many thanks go to Mr Michael Shaw and Dr 
Carmen Salafia for performing some of the 
procedures carried out on the group of patients in 
this study. No funding/financial disclosures/ 
conflicts of interest to declare.  The manuscript is 
the sole work of the authors.   
 
References 
1.  Chui J, Coroneo MT, Tat LT,  Crouch R, Wakefield D, 
Di Girolamo N (2011) Ophthalmic Pterygium: A Stem 
Cell Disorder with Premalignant Features. American 
Journal of Pathology 178(2):817–27. 
2.  D'Ombrain A (1948) The Surgical Treatment of 
Pterygium. Br J Ophthalmol 32(2):65–71. 
3.  Sirisha G, Jyothi S, Chowdary NL (2016) Autologous 
Blood For Conjunctival Autograft Fixation in 
Pterygium Surgery. Indian Journal of Applied Research 
6(4):328-30. 
4.  Prabhasawat P, Barton K, Burkett G, Tseng SC (1997) 
Comparison of conjunctival autografts, amniotic 
membrane grafts, and primary closure for pterygium 
excision. Ophthalmology 104(6):974-85. 
5.  Verweij J, Pinedo H (1990) Mitomycin C: mechanism 
of action, usefulness and limitations. Ant-Cancer Drugs 
1(1):5-13. 
6.  Singh G, Wilson M, Foster C (1998)  Mitomycin eye 
drops as treatment for pterygium. Ophthalmology 
95:813-20. 
7.  M R Fallah, M R Golabdar, J Amozadeh, M A Zare, 
S Moghimi and G Fakhraee (2008) Transplantation of 
conjunctival limbal autograft and amniotic membrane 
vs mitomycin and amniotic membrane in treatment of 
recurrent pterygium. Eye 22:420–4. 
8.  Frucht-Pery J, Ilsar M (1994) The use of low-dose 
mitomycin C for prevention of recurrent pterygium. 
Ophthalmology 101:7597-662. 
9.  Singh G, Wilson M, Foster C (1990) Long term follow 
up study of mitomycin eye drops as adjunctive 
treatment of pterygia and its comparison with 
conjunctival autograft transplantation. Cornea 9:331-4. 
 
 
10.  Sánchez-Thorin JC, Rocha G, Yelin JB (1998) Meta-
analysis on the recurrence rates after bare sclera 
resection with and without mitomycin C use and 
conjunctival autograft placement in surgery for primary 
pterygium. Br J Ophthalmol 82:661–5.  
11.  Manning C, Kloess P, Diaz M (1997) Intraoperative 
mitomycin in primary pterygium excision. A 
prospective randomised trial. Ophthalmology 104:844-
8. 
12.  Young A, Leung GY, Wong AK, Cheng LL, Lam DS 
(2004) A randomised trial comparing 0.02% mitomycin 
C and limbal conjunctival autograft after excision of 
primary pterygium. Br J Ophthalmol 88:995-7. 
13.  Vergés C (2012) Recurrent pterygium, how to diagnose 
and how to treat.  Available at 
https://pterigion.net/2012/11/29/recurrent-pterygium-
how-to-diagnose-and-how-to-treat/. Accessed 06 June 
2016. 
14.  Lewallen S (1989) A randomized trial of conjunctival 
autografting for pterygium in the tropics. 
Ophthalmology 96(11):1612-4  
15.  Raiskup F, Solomon A, Landau D, Ilsar M, Frucht-Pery 
J (2004) Mitomycin C for pterygium: long term 
evaluation. Br J Ophthalmol 88(11):1425-8. 
16.  Yaisawand S, Piyapattanakorn P (2003) Role of post-
operative topical corticosteroids in recurrence rate after 
pterygium excision with conjunctival autograft. J Med 
Assoc Thai. 86 Suppl 2:S215-23. 
 
 
9
